Evidence map›Paper›PMID 23926923›Full record

ArticleHistopathology2013

Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.

Matthew J Oberley, Saurabh A Rajguru, Chong Zhang, Kyungmann Kim, Gene R Shaw, Kreg M Grindle, Brad S Kahl, Craig Kanugh, Jennifer Laffin, David T Yang

Open access · greenAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Histopathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. The pathologic diagnosis of mantle cell lymphoma.Histology and histopathology · 2021
    Review
  5. EGR1 Addiction in Diffuse Large B-cell Lymphoma.Molecular cancer research : MCR · 2021
    Article
  6. Haematologica · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Mantle cell lymphoma--a spectrum from indolent to aggressive disease.Virchows Archiv : an international journal of pathology · 2016
    Review
  15. Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies.The Journal of biological chemistry · 2016
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Matthew J OberleyDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, USA.
Saurabh A Rajguru
Chong Zhang
Kyungmann Kim
Gene R Shaw
Kreg M Grindle
Brad S Kahl
Craig Kanugh
Jennifer Laffin
David T Yang
University of Wisconsin–Madison · USUniversity of Wisconsin Carbone Cancer Center · USMarshfield Clinic · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
NCATS NIH HHS 9U54TR000021NCATS NIH HHS UL1 TR000427NCI NIH HHS P30 CA014520NCRR NIH HHS 1UL1RR025011NCRR NIH HHS UL1 RR025011
6 · The paper itself

Abstract

aimTo assess the validity and potential clinical utility of evaluating MYC expression by immunohistochemistry (IHC) in mantle cell lymphoma (MCL). METHODS AND

resultsMYC IHC was scored on a tissue microarray containing 62 MCLs and 29 controls by two pathologists. Inter-observer correlation was high (intra-class correlation of 0.98). MYC IHC scores correlated with MYC expression (Spearman's rank correlation 0.69, P < 0.0001) and weakly with Ki67 proliferation index (Spearman's rank correlation 0.30, P = 0.03). Six blastic MCLs did not have higher mean MYC IHC scores or MYC mRNA expression than non-blastic MCLs. None of 57 cases assessed, including all of the blastic cases, showed MYC rearrangement by fluorescence in-situ hybridization. Multivariate analysis with backward selection from potential predictors including age, lactate dehydrogenase, leukocyte count, MIPI score, ECOG performance status, blastic morphology and Ki67 index showed that MYC IHC score is an independent predictor of progression-free survival (hazard ratio 2.34, 95% CI 1.42-3.88, P = 0.0009) and overall survival (hazard ratio 1.90, 95% CI 1.05-3.43, P = 0.034).

conclusionsWe show that a new monoclonal anti-MYC antibody can enable accurate and reproducible visual assessment of MYC expression that is independently predictive of clinical outcomes in MCL.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDisease-Free SurvivalFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceKaplan-Meier EstimateLymphoma, Mantle-CellMaleMiddle AgedProportional Hazards ModelsProto-Oncogene Proteins c-mycRNA, MessengerBiomarkers, TumorMYC protein, humanProto-Oncogene Proteins c-mycRNA, Messengerimmunohistochemistrymantle cell lymphomaMYCtissue microarray

Identifiers

PMID23926923
PMCPMC3871984
OpenAlexW1974884209

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.